23
total announcements
AAREYDRUGS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹363 Cr
P/E (TTM)
77.5
EPS (TTM)
₹1.47
52W Low
₹50.31
52W High
₹114.80
Dividend Yield
0.00%
Beta
1.24
Price / Book
2.2
Debt / Equity
40.4
Revenue (TTM)
₹415 Cr
Gross Margin
3.82%
Operating Margin
1.07%
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about the allotment of 11,50,000 Equity Shares pursuant to Conversion of Warrants. The company has approved the allotment of equity shares upon receipt of Rs. 47.85/- per warrant, aggregating to Rs. 5,50,27,500/- to the persons belonging to both promoter and non-promoter Category.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report and voting results of Annual General Meeting held on September 30, 2026.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed about the disclosure of material issue under Regulation 29(2) read with Regulation 29(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company has allotted shares to its promoters and promoter group, resulting in a change in their shareholding percentages.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed about the disclosure of a material issue, specifically the acquisition of 1,50,000 equity shares by Nimit Rajesh Ghatalia, resulting in a post-allotment holding of 16,50,000 (5.18%) equity shares.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed about the allotment of equity shares to promoters due to the conversion of warrants.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited held its 36th Annual General Meeting on September 30, 2026, where the company's financial performance for the FY 2025-2026 was discussed, and resolutions were passed, including the appointment of a director and approval of related party transactions.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026 and September 30, 2026. The company has approved the allotment of 11,50,000 Equity Shares of Rs. 10/- each pursuant to Conversion of Fully Convertible Equity Share Warrants upon receipt of Rs. 47.85/- per warrant.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026, where the Board of Directors approved the allotment of 11,50,000 Equity Shares of Rs. 10/- each pursuant to Conversion of Fully Convertible Equity Share Warrants.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. Worth Investment & Trading Co Limited has also informed the Exchange regarding the Trading Window closure for its insiders.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about the AGM Intimation letter that has been sent to the Shareholders under Regulation 36(1)(b) of the SEBI Listing Regulations, 2015, providing the web link from where the Integrated Annual Report can be accessed on the Company's website.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about the publication of the Notice of 36th AGM in the newspaper e News Hub and o News Hub.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026, along with the Integrated Annual Report for the financial year 2025-26.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the book closure and e-voting period for the 36th Annual General Meeting.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026, where the Board of Directors considered and approved the Draft of Board Report and its Annexure and Annual Report along with notice for calling the 36th Annual General Meeting of the Company for the Financial Year 31st March 2026.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has published a copy of a newspaper advertisement regarding unaudited financial results for the quarter and three months ended June 30, 2026, and a notice regarding a property dispute.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and the board of directors has approved the results along with a limited review report and MD/CFO certification.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the allotment of 2,520,000 equity shares upon the conversion of 2,500,000 convertible warrants. The warrants were issued on a preferential basis at an offer price of Rs. 63.80 per warrant. The allotment was approved by the Board of Directors on August 6, 2026. The company's issued and paid-up capital will increase to Rs. 33,35,430,000.
Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities received for dematerialisation during the quarter ended 30th June 2026.